MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
Golden Decade of Defence
Potential 33x Opportunity by 2030
- Home
- Stock Quote
- REMEDIUM LIFECARE
REMEDIUM LIFECARE Share Price (REME)
Here is the latest stock price and chart of REMEDIUM LIFECARE. For more details, see the REMEDIUM LIFECARE company fact sheet and quarterly results.
| Live BSE Quotes | Mar 24, 2023 (Close) | ||
|---|---|---|---|
| Price (Rs)607.45 | Open (Rs) 607.45 | High (Rs) 607.45 | Low (Rs) 607.45 |
| % Change5.00 | Volume 743 | Value (Rs) 451,335 | 52-Week H/L 607.45 / 134.50 |
| Live NSE Quotes |
|---|
| Not listed |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day 5.00% | 1 Month 145.98% | 3 Months 333.89% | 1 Year 338.59% | ||
| Valuation | ||||
|---|---|---|---|---|
| EPS (Rs)* 25.12 | P/E Ratio (x) 24.19 | Market Cap (Rs m) 2,186.82 | P/BV (x) 14.44 | Dividend Yield (%) 0.00 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
REMEDIUM LIFECARE Share Price Today:
REMEDIUM LIFECARE last traded price had surged 5.0% to Rs 607.5 on the BSE. The total volume of shares traded was 0.0 m.
Overall, the benchmark S&P BSE SENSEX was at 57,527.1 (down 0.7%).
Over the last 30 days, the REMEDIUM LIFECARE share price is up 158.2%. And over the last one year, REMEDIUM LIFECARE share price is up 343.4%.
The current market capitalisation of REMEDIUM LIFECARE stands at Rs 2,186.82 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of December 2022, company promoters held 1.11% stake in REMEDIUM LIFECARE, with no shares having been pledged. To know more, check out the latest shareholding pattern of REMEDIUM LIFECARE.
FAQs on REMEDIUM LIFECARE
What is the REMEDIUM LIFECARE share price today?
The last traded price of REMEDIUM LIFECARE was Rs 607.5 on the BSE, up 5.0% over the previous close.
What is the market cap of REMEDIUM LIFECARE?
The current market capitalisation of REMEDIUM LIFECARE stands at Rs 2,187 m.
What is the Earnings per share (EPS) of REMEDIUM LIFECARE?
REMEDIUM LIFECARE had an EPS of Rs 25.1 in the latest financial year.
Today's Market
Sensex Today Ends 390 Points Lower | Bajaj Finance Slips 4% | Adani Enterprises & Tata Steel Top Losers(Closing)
After making a flat start, Indian share markets fell sharply during closing hours and ended lower for the second straight session.
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks
TRENDING TOPICS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.